scispace - formally typeset
Open AccessJournal ArticleDOI

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro

Toshio Fujino, +10 more
- 01 Oct 2019 - 
- Vol. 14, Iss: 10, pp 1753-1765
Reads0
Chats0
TLDR
MET-TKIs inhibited the growth of cells with MET exon 14 mutations, and this finding should provide relevant clinical implication for treating patients with lung cancer harboring MET ex on 14 mutations.
About: 
This article is published in Journal of Thoracic Oncology.The article was published on 2019-10-01 and is currently open access. It has received 91 citations till now. The article focuses on the topics: Point mutation & Mutation.

read more

Citations
More filters
Journal ArticleDOI

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Paul K. Paik, +34 more
- 28 May 2020 - 
TL;DR: Among patients with advanced NSCLC with a confirmed MET exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients, and adverse events led to permanent discontinuation of tEPotinib in 11% of the patients.
Journal ArticleDOI

MET-dependent solid tumours - molecular diagnosis and targeted therapy

Robin Guo, +6 more
- 08 Jun 2020 - 
TL;DR: The utility of various diagnostic techniques and the roles of different classes of MET-targeted therapies in cancers with MET amplification, mutation and fusion, and MET overexpression are evaluated.
Journal ArticleDOI

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.

Gonzalo Recondo, +26 more
- 07 Feb 2020 - 
TL;DR: A deeper understanding of molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors can support the development of sequential or combinatorial therapeutic strategies to overcome resistance.
Journal ArticleDOI

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

Takamasa Koga, +13 more
- 01 Aug 2021 - 
TL;DR: In this article, the secondary KRAS mutations were identified in the presence of Nethyl-N-nitrosourea and a combination of the SOS1 inhibitor, BI-3406, and trametinib had potent activity against this resistance.
Journal ArticleDOI

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.

Giuseppe Lamberti, +7 more
- 01 Dec 2020 - 
TL;DR: The clinicopathological features, the emerging targeted therapies and mechanisms of resistance and strategies to overcome them of KRAS, BRAF, MET, RET, HER2 and NTRK-addicted advanced NSCLCs are reviewed.
References
More filters
Journal ArticleDOI

Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network

Eric A. Collisson, +318 more
- 01 Jan 2014 - 
TL;DR: In this paper, the authors report molecular profiling of 230 resected lung adnocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses.
Journal ArticleDOI

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Lecia V. Sequist, +21 more
- 23 Mar 2011 - 
TL;DR: Detailed genetic and histological analysis of 37 patients with drug-resistant non–small cell lung cancers carrying EGFR mutations provides new insights into the shifting sands of drug resistance evolution in lung cancers and suggests that serial biopsies may be essential in the quest to reverse or even prevent the development ofdrug resistance.

Comprehensive molecular profiling of lung adenocarcinoma

Eric S. Lander
TL;DR: High rates of somatic mutation were seen, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification, and MAPK and PI(3)K pathway activity was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation.
Journal ArticleDOI

Somatic mutations affect key pathways in lung adenocarcinoma

Li Ding, +96 more
- 23 Oct 2008 - 
TL;DR: Somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B are found.
Journal ArticleDOI

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

Marcin Imielinski, +57 more
- 14 Sep 2012 - 
TL;DR: Exome and genome sequences and whole-genome sequence analysis revealed frequent structural rearrangements, including in-frame exonic alterations within EGFR and SIK2 kinases, which are attractive targets for biological characterization and therapeutic targeting of lung adenocarcinoma.
Related Papers (5)

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors

Garrett M. Frampton, +37 more
- 13 May 2015 - 

MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

Mark M. Awad, +12 more
- 04 Jan 2016 - 

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.

Joanna H.M. Tong, +15 more
- 15 Jun 2016 - 

Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer

Geometry mono Investigators
- 02 Sep 2020 - 

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

Paul K. Paik, +14 more
- 13 May 2015 -